Journal of Pharmaceutical Sciences & Emerging DrugsISSN: 2380-9477

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Short Communication, J Pharm Sci Emerg Drugs Vol: 6 Issue: 1

Eteplirsen: Unattainable Attained

Mukta Sharma1*, Naina Goel1,2 and Ashwin K Jainarayanan1,3

1CSIR- Institute of Genomics and Integrative Biology, New Delhi, India

2Center for Research and Interdisciplinarity, Paris, France

3Indian Institute of Science Education and Research, Mohali, India

*Corresponding Author : Mukta Sharma
CSIR-Institute of Genomics and Integrative Biology, New Delhi, India

Received: September 05, 2017 Accepted: July 17, 2018 Published: July 24, 2018

Citation: Sharma M, Goel N, Jainarayanan AK (2018) Eteplirsen: Unattainable Attained. J Pharm Sci Emerg Drugs 6:1. doi: 10.4172/2380-9477.1000127


Rare diseases are highly diverse and it is critical to know the signs that predict the development, progression and manifestation of disease. Though a very small number of people get affected by the rare diseases but its impact is outrageous, Duchenne Muscular Dystrophy (DMD) being one such rare genetic disorder is characterized by progressive muscle deterioration and wasting. An overall estimate of prevalence of DMD reflects 30 per 100,000 populations (1 in 3000 or~0.029%).

Keywords: Eteplirsen; Duchenne Muscular Dystrophy

international publisher, scitechnol, subscription journals, subscription, international, publisher, science

Track Your Manuscript

Awards Nomination

open access